Andreas Leiherer
Overview
Explore the profile of Andreas Leiherer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
642
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muendlein A, Brandtner E, Schimpf J, Piribauer M, Geiger K, Heinzle C, et al.
Kidney360
. 2025 Mar;
PMID: 40063102
Background: Glypican-4 (GPC4) is a cell-surface heparan sulfate proteoglycan that can be released into circulation under various clinical conditions. Elevated levels of circulating GPC4 have recently been associated with reduced...
2.
Schnetzer L, Leiherer A, Festa A, Mundlein A, Plattner T, Mayer G, et al.
Eur J Clin Invest
. 2024 Dec;
55(3):e14374.
PMID: 39704124
Background: Both chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) confer a high risk of cardiovascular disease and mortality. These entities frequently coincide. The separate and joint impact...
3.
Leiherer A
Int J Mol Sci
. 2024 Dec;
25(23).
PMID: 39684521
Machine learning (ML) and bioinformatics are catalyzing a new era in biomedical research, enabling unprecedented insights into the complex systems that govern human health and disease [...].
4.
Drexel H, Mader A, Larcher B, Festa A, Vonbank A, Fraunberger P, et al.
Atherosclerosis
. 2024 Dec;
401:119048.
PMID: 39632214
Background: Remnant cholesterol (RC), defined as non-HDL-non-LDL cholesterol, has attracted recent scientific interest as a candidate lipid factor for residual cardiovascular risk. Despite a rising amount of epidemiologic information, there...
5.
Neyer M, Vogel J, Elsner P, Kuehrer H, Saely C, Muendlein A, et al.
Diabetes Obes Metab
. 2024 Nov;
27(2):835-844.
PMID: 39604296
Aim: Over recent years, therapy options and strategies for type 2 diabetes mellitus (T2DM) have developed substantially. This study investigated glucose-lowering treatment in patients with high cardiovascular risk over three...
6.
Mink S, Saely C, Leiherer A, Reimann P, Frick M, Cadamuro J, et al.
JCI Insight
. 2024 Oct;
9(20).
PMID: 39435658
BACKGROUNDDespite the currently prevailing, milder Omicron variant of COVID-19, older adults remain at elevated risk of hospital admission, critical illness, and death. Loss of efficacy of the immune system, including...
7.
Mink S, Drexel H, Leiherer A, Cadamuro J, Hitzl W, Frick M, et al.
Vaccines (Basel)
. 2024 Aug;
12(8).
PMID: 39203980
Objectives: Despite the currently prevailing, milder Omicron variant, coronary artery disease (CAD) patients constitute a major risk group in COVID-19, exhibiting 2.6 times the mortality risk of non-CAD patients and...
8.
Vogel J, Neyer M, Elsner P, Vonbank A, Plattner T, Saely C, et al.
J Clin Med
. 2024 Jun;
13(11).
PMID: 38892897
A complete medication plan (MPlan) increases medication safety and adherence and is crucial in care transitions. Countries that implemented a standardized MPlan reported benefits on patients' understanding and handling of...
9.
Leiherer A, Muendlein A, Mink S, Mader A, Saely C, Festa A, et al.
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791370
Metabolomics, with its wealth of data, offers a valuable avenue for enhancing predictions and decision-making in diabetes. This observational study aimed to leverage machine learning (ML) algorithms to predict the...
10.
Ratz M, Vogel J, Kuhrer H, Saly C, Mundlein A, Vonbank A, et al.
Wien Klin Wochenschr
. 2024 May;
PMID: 38743139
Background And Aim: Guidelines on dyslipidemia and lipid-lowering therapy (LLT) over the years recommend lower low-density lipoprotein cholesterol (LDL-C) goals by more intense therapy. Nevertheless, LDL‑C has increased in the...